JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, T-Cell, Cutaneous

Interventions: Drug: Quisinostat, 12 mg

First Posted Date: 2011-12-06

Last Posted Date: 2016-11-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 26

Registration Number: NCT01486277

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Phase 2

Completed

Conditions: High-risk Smoldering Multiple Myeloma

Interventions: Drug: Placebo
Drug: Siltuximab

First Posted Date: 2011-12-02

Last Posted Date: 2020-01-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 85

Registration Number: NCT01484275

A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Plasma Volume

Interventions: Drug: Canagliflozin
Drug: Placebo

First Posted Date: 2011-12-01

Last Posted Date: 2014-08-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 36

Registration Number: NCT01483781

A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate

Phase 2

Withdrawn

Conditions: Active Rheumatoid Arthritis; Rheumatoid Arthritis

Interventions: Drug: Placebo/JNJ-39758979 (300 mg/d)
Drug: JNJ-39758979 (10 mg)
Drug: JNJ-39758979 (30 mg)
Drug: JNJ-39758979 (100 mg)
Drug: JNJ-39758979 (300 mg)

First Posted Date: 2011-11-28

Last Posted Date: 2016-12-01

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT01480388

Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Drug: RA-18C3

First Posted Date: 2011-11-18

Last Posted Date: 2021-02-17

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 11

Registration Number: NCT01474798

Locations: 🇺🇸
Meridien Research, Saint Petersburg, Florida, United States
🇺🇸
Moy, Fincher, and Chipps Facial Plastics and Dermatology, Beverly Hills, California, United States
🇺🇸
Austin Dermatology Associates, Austin, Texas, United States

A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: JNJ-2641585 / VELCADE / Dexamethasone

First Posted Date: 2011-11-03

Last Posted Date: 2020-01-22

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT01464112

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2011-11-02

Last Posted Date: 2012-11-21

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 74

Registration Number: NCT01463774

A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)

First Posted Date: 2011-11-01

Last Posted Date: 2012-08-22

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 83

Registration Number: NCT01463228

Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)
Drug: B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)

First Posted Date: 2011-10-25

Last Posted Date: 2013-02-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 24

Registration Number: NCT01459094

A Study to Evaluate the Bioavailability and Food Effect of JNJ-39439335 in Healthy Adult Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-39439335

First Posted Date: 2011-10-18

Last Posted Date: 2013-01-31

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 43

Registration Number: NCT01454245

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy